Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers

Oct 14 (Reuters) - Arrowhead Pharmaceuticals, Inc. ARWR.O:

• ARROWHEAD PHARMACEUTICALS ANNOUNCES ARO-MAPT INTERIM PHASE 1/2A CLINICAL DATA DEMONSTRATING DEEP AND DURABLE TAU REDUCTIONS IN HEALTHY VOLUNTEERS

• ARROWHEAD PHARMACEUTICALS - TO COMPLETE DOSING IN HEALTHY VOLUNTEERS, DATA UPDATES EXPECTED IN 2027

• ARROWHEAD PHARMACEUTICALS - ARO-MAPT GENERALLY WELL TOLERATED, MOST ADVERSE EVENTS MILD, NO SERIOUS TEAES REPORTED

Further company coverage: ARWR.O